Eli Lilly bets big again on Alzheimer's drug
This article was originally published in Scrip
Executive Summary
Brushing off questions about the cost of another Alzheimer’s drug study, Eli Lilly & Co. executives said they are set to enroll people in the next late-stage trial of the company’s solanezumab.